secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001104659-24-084159
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics receives FDA Rare Pediatric Drug Designation for VCN-01 in retinoblastoma
--------------------------------------------------------------------------------

- FDA grants Rare Pediatric Drug Designation for VCN-01, a stroma-degrading oncolytic adenovirus, to treat retinoblastoma.
- Prior orphan drug designation for same indication; RPDD may provide a Priority Review Voucher upon BLA approval.
- Holders of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 common shares at $1.22 per share.
- Positive Phase 1 results from investigator-sponsored trial of intravitreal VCN-01 in pediatric refractory retinoblastoma inform clinical pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/0001104659-24-084159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924084159/tm2420486d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer